Is Artiva Biotherapeutics, Stock a Good Investment?
Artiva Biotherapeutics, Investment Advice | ARTV |
- Examine Artiva Biotherapeutics,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Artiva Biotherapeutics,'s leadership team and their track record. Good management can help Artiva Biotherapeutics, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Artiva Biotherapeutics,'s business and its evolving consumer preferences.
- Compare Artiva Biotherapeutics,'s performance and market position to its competitors. Analyze how Artiva Biotherapeutics, is positioned in terms of product offerings, innovation, and market share.
- Check if Artiva Biotherapeutics, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Artiva Biotherapeutics,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Artiva Biotherapeutics, Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Artiva Biotherapeutics, Common is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Artiva Biotherapeutics, Stock
Researching Artiva Biotherapeutics,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.33. Some equities with similar Price to Book (P/B) outperform the market in the long run. Artiva Biotherapeutics, recorded a loss per share of 2.48. The entity had not issued any dividends in recent years.
To determine if Artiva Biotherapeutics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Artiva Biotherapeutics,'s research are outlined below:
| Artiva Biotherapeutics, had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 33.49 M. Net Loss for the year was (28.72 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Artiva Biotherapeutics, generates negative cash flow from operations | |
| Artiva Biotherapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are held by institutions such as insurance companies |
Earnings surprises can significantly impact Artiva Biotherapeutics,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Artiva Biotherapeutics,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-13 | 2024-09-30 | -0.635 | -0.8729 | -0.2379 | 37 | ||
2024-08-29 | 2024-06-30 | -4.4 | -22.0 | -17.6 | 400 |
Artiva Biotherapeutics,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 268.15 M.Market Cap |
|
Artiva Biotherapeutics,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.28) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.26) | (0.28) | |
| Return On Equity | 0.17 | 0.16 |
Determining Artiva Biotherapeutics,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Artiva Biotherapeutics, is a good buy. For example, gross profit margin measures Artiva Biotherapeutics,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Artiva Biotherapeutics,'s profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Artiva Biotherapeutics,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Artiva Biotherapeutics, Common. Check Artiva Biotherapeutics,'s Beneish M Score to see the likelihood of Artiva Biotherapeutics,'s management manipulating its earnings.
Basic technical analysis of Artiva Stock
As of the 19th of December, Artiva Biotherapeutics, shows the Risk Adjusted Performance of 0.0561, downside deviation of 6.33, and Mean Deviation of 5.09. Artiva Biotherapeutics, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Artiva Biotherapeutics, variance and potential upside to decide if Artiva Biotherapeutics, is priced correctly, providing market reflects its regular price of 11.04 per share. Given that Artiva Biotherapeutics, has jensen alpha of 0.376, we suggest you to validate Artiva Biotherapeutics, Common's prevailing market performance to make sure the company can sustain itself at a future point.Artiva Biotherapeutics,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Artiva Biotherapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Artiva Biotherapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Artiva Biotherapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Artiva Biotherapeutics,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Artiva Biotherapeutics,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0561 | |||
| Market Risk Adjusted Performance | 0.5553 | |||
| Mean Deviation | 5.09 | |||
| Semi Deviation | 6.2 | |||
| Downside Deviation | 6.33 | |||
| Coefficient Of Variation | 1680.49 | |||
| Standard Deviation | 6.72 | |||
| Variance | 45.1 | |||
| Information Ratio | 0.0552 | |||
| Jensen Alpha | 0.376 | |||
| Total Risk Alpha | 0.2281 | |||
| Sortino Ratio | 0.0585 | |||
| Treynor Ratio | 0.5453 | |||
| Maximum Drawdown | 32.08 | |||
| Value At Risk | (10.48) | |||
| Potential Upside | 10.28 | |||
| Downside Variance | 40.07 | |||
| Semi Variance | 38.41 | |||
| Expected Short fall | (5.49) | |||
| Skewness | 0.3934 | |||
| Kurtosis | 0.9563 |
| Risk Adjusted Performance | 0.0561 | |||
| Market Risk Adjusted Performance | 0.5553 | |||
| Mean Deviation | 5.09 | |||
| Semi Deviation | 6.2 | |||
| Downside Deviation | 6.33 | |||
| Coefficient Of Variation | 1680.49 | |||
| Standard Deviation | 6.72 | |||
| Variance | 45.1 | |||
| Information Ratio | 0.0552 | |||
| Jensen Alpha | 0.376 | |||
| Total Risk Alpha | 0.2281 | |||
| Sortino Ratio | 0.0585 | |||
| Treynor Ratio | 0.5453 | |||
| Maximum Drawdown | 32.08 | |||
| Value At Risk | (10.48) | |||
| Potential Upside | 10.28 | |||
| Downside Variance | 40.07 | |||
| Semi Variance | 38.41 | |||
| Expected Short fall | (5.49) | |||
| Skewness | 0.3934 | |||
| Kurtosis | 0.9563 |
Consider Artiva Biotherapeutics,'s intraday indicators
Artiva Biotherapeutics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Artiva Biotherapeutics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Artiva Biotherapeutics, time-series forecasting models is one of many Artiva Biotherapeutics,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Artiva Biotherapeutics,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Artiva Stock media impact
Far too much social signal, news, headlines, and media speculation about Artiva Biotherapeutics, that are available to investors today. That information is available publicly through Artiva media outlets and privately through word of mouth or via Artiva internal channels. However, regardless of the origin, that massive amount of Artiva data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Artiva Biotherapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Artiva Biotherapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Artiva Biotherapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Artiva Biotherapeutics, alpha.
Artiva Biotherapeutics, Corporate Management
| David Moriarty | Senior Operations | Profile | |
| Christopher Horan | Chief Officer | Profile | |
| Thorsten MD | Chief Officer | Profile | |
| Eugene Helsel | Senior Affairs | Profile |
Already Invested in Artiva Biotherapeutics, Common?
The danger of trading Artiva Biotherapeutics, Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Artiva Biotherapeutics, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Artiva Biotherapeutics,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Artiva Biotherapeutics, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.